Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study
Mariantonietta Colozza(Azienda Ospedaliera di Perugia), Maurizio Tonato, Carmelina Rodinò(Guglielmo da Saliceto Hospital), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Anna Maria Mosconi(Azienda Ospedaliera di Perugia), C. Boni(Ospedale Santa Maria), Giancarlo Bisagni, Roberto Sabbatini(Azienda Ospedaliero-Universitaria di Modena), Alberto Rosa Bian, Giorgio Cocconi, Rodolfo Passalacqua(Champalimaud Foundation), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Verena De Angelis(University of Perugia), Sofia Di Sarra(University of Parma), Ermanno Rondini(Santa Maria Nuova Hospital), R Algeri(Ospedale Misericordia - Grosseto)
Cited by 14
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k